Datapoint: Keytruda Scores First-Line Esophageal Cancer Nod
The FDA last week approved Merck & Co.’s Keytruda for the treatment of newly diagnosed esophageal or gastroesophageal junction carcinoma in tandem with chemotherapy. Keytruda is the first PD-1/L1 agent to be approved as a first-line therapy for this type of cancer. The drug was approved as a third-line treatment for gastric or gastroesophageal junction cancer in 2017, an indication where it holds preferred formulary placement for 6% of covered lives under the pharmacy benefit.
SOURCE: MMIT Analytics, as of 3/24/21